Eight programs selected
The portfolio includes sirolimus for Pendred syndrome/DFNB4, a LAT1 inhibitor in biliary tract cancer, CTX-712 in AML/MDS, an oncolytic virus for rare soft-tissue tumors and anti-CCR4 CAR-T for T-cell malignancies.
How to read this
These are R&D support selections, not approved therapies. LINK MT will track trial countries, sites, enrollment and PMDA milestones.
Official source
Research, clinical trials and approved treatments are presented separately. This page is general information, not individual medical advice.